TORONTO, Aug. 28, 2015 /CNW/ - Syncordia Technologies
and Healthcare Solutions, Corp. (TSXV: SYN) ("Syncordia" or the
"Company") today reported financial results for the three months
ended June 30, 2015.
Reported results reflect three months of operations of Health
Services Integration Inc. ("HSI"), which was acquired effective
October 31, 2014, and 67 days of
operations of Paragon Billing LLC, ("Paragon") which was acquired
April 24, 2015. Syncordia had no
segment operational activities for the period ended June 30, 2014. All results are reported in US
dollars and are prepared in accordance with International Financial
Reporting Standards ("IFRS").
Financial Highlights
- Revenue from the RCM segment was $3.4
million.
- Adjusted EBITDA before Corporate and Syncordia Cloud segment
costs were $1.6 million.
- Adjusted EBITDA was $0.6
million.
- Cash and cash equivalents were $10.3
million at June 30, 2015.
Business Highlights
- Hired a seasoned team of software engineers, developers, and
designers to support the development of Syncordia Cloud, our
cloud-based service offering.
- Acquired Paragon Billing LLC, a leading provider of Behavioural
Health medical billing and electronic health records.
- Raised CDN$10.0 million of
equity.
- Signed two contracts with Nevada counties for ground ambulance RCM
billing services.
Highlights Subsequent to First Quarter Fiscal 2016
- Commenced trading under the symbol "SYN" on the TSX Venture
Exchange July 8, 2015.
Management Commentary
"We are pleased with our
performance across both operating entities as we further expanded
our customer base," said Michael
Franks, Chief Executive Officer at Syncordia. "Of particular
note, we signed contracts with Elko and Eureka Counties in Nevada, further expanding our geographic
customer base in the State. We are committed to growing our EBITDA
and will continue to make measured investments in our business.
Additionally, we are actively engaged in negotiations with several
acquisition candidates and continue to build a promising pipeline
of targets."
Q1 2016 Financial Results
Revenue from the RCM segment
was $3.4 million, segmented between
air transportation client billings of $2.7
million, ground transportation client billings of
$0.1 million, behavioural health
client billings of $0.3 million as
well as other RCM related revenue streams of $0.2 million.
Gross margin was $2.4 million or
70% of revenue.
Adjusted EBITDA before Corporate costs was $1.3 million or 37% of revenue, representing
$1.6 million of Adjusted EBITDA from
our RCM segment less $0.3 million of
Syncordia Cloud segment costs.
Corporate costs were $0.6 million,
primarily reflecting salaries and benefits and professional fees
and increased by $0.6 million from
the prior period due to the scale-up of our operating
activities.
Adjusted EBITDA was $0.6 million,
or 18% of revenue.
Business Outlook
Our outlook of the business for the
remainder of fiscal 2016 remains unchanged from our annual MD&A
released on July 28, 2015.
We believe that operating improvements and competitive
positioning of our RCM business along with favourable industry
trends will allow us to meaningfully grow our RCM business. We also
believe that our Syncordia Cloud business will experience growth as
a result of introducing a suite of proprietary products that
address unique problems being faced by industry participants.
We anticipate continued investment in the development of our
Syncordia Cloud business in line with growing market demand for
cloud-based service offerings and the profitability of our
business.
Change to Board of Directors
In addition, Syncordia is
announcing the departure of Ken
Stults from its Board of Directors. Mr. Stults, the prior
owner of HSI, joined the Board of Directors immediately after the
acquisition of HSI as part of a post-closing integration strategy.
That integration has come to an end and Mr. Stults has decided to
leave his position on the Board to pursue other business interests.
Mr. Stults says "I wish HSI and team the best of luck into the
future." Michael Franks, the Chief
Executive Officer, says "It was a pleasure to spend time with Ken
and to build upon a great company he created over many years. The
entire Syncordia team would like to thank Ken for his support and
commitment."
Notice of Conference Call
Syncordia will hold a
conference call on Monday, August 31,
2015, at 8:00 a.m (ET) to discuss its financial results and
other corporate developments. To access the conference call by
telephone, dial 647-427-7450 or 1-888-231-8191. A live audio
webcast will be available through www.syncordiahealth.com or
http://bit.ly/1KSUN3P. An archived replay of the webcast will be
available for 90 days. A presentation will accompany the conference
call and will be available for download from the Investor Relations
section of Syncordia's website at
http://www.syncordiahealth.com/company/investor-relations/events-presentations/.
Forward Looking Statements
Certain statements herein
may be "forward looking" statements that involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Syncordia or the industry
to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Forward looking statements involve significant risks
and uncertainties, should not be read as guarantees of future
performance or results, and will not necessarily be accurate
indications of whether or not such results will be achieved. A
number of factors could cause actual results to vary significantly
from the results discussed in the forward looking statements. These
forward looking statements reflect current assumptions and
expectations regarding future events and operating performance and
are made as of the date hereof and we assume no obligation, except
as required by law, to update any forward looking statements to
reflect new events or circumstances.
Cautionary Note Regarding Non-IFRS Measures
This press
release contains references to "EBITDA," "Adjusted EBITDA," and
"Adjusted EBITDA before Corporate costs."
Management defines EBITDA as Earnings before Interest, Taxes,
Depreciation and Amortization.
Management defines Adjusted EBITDA as Earnings before Interest,
Taxes, Depreciation, Amortization, Transaction Costs, Fair Value
Gains / Losses, Stock Based Compensation and Cash based Share
Compensation Arrangements. Transaction costs include professional
and other fees associated with business transactions.
Management defines Adjusted EBITDA before Corporate costs as
Earnings before Interest, Taxes, Depreciation, Amortization,
Transaction Costs, Fair Value Gains / Losses, Stock Based
Compensation, Cash based Share Compensation Arrangements and costs
of our Corporate segment. This metric is used to assess the
performance of RCM and Syncordia cloud segments.
Corporate costs include sales and marketing, general and
administrative and research and development, less amortization and
depreciation, stock-based compensation expense and stock
compensation indexed to our share price.
Management believes that EBITDA and Adjusted EBITDA are useful
supplemental measure of our operating performance. However, neither
EBITDA nor Adjusted EBITDA are recognized earnings measure under
IFRS and neither have a standardized meaning prescribed by IFRS.
Therefore, EBITDA and Adjusted EBITDA may not be comparable to
similar measures presented by other issuers. Neither EBITDA nor
Adjusted EBITDA should be construed as an alternative to net income
or loss.
About Syncordia Technologies and Healthcare Solutions,
Corp.
We are a technology enhanced revenue cycle management
("RCM") company focused on underserved niche segments of the
healthcare industry. Our growth strategy is to acquire RCM
businesses with and without software and, improve their
profitability by increasing revenues and operating efficiencies
using our software, and in time, commercializing the Syncordia
Cloud, our cloud-based software offering, to provide customer
demanded turn-key solutions from a single provider and to address
compelling RCM market opportunities.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
The following is a reconciliation of EBITDA with net loss and
comprehensive loss:
|
|
|
(in thousands of U.S.
Dollars)
|
|
|
|
Three
Months
ended June
30
2015
|
Three
Months
ended June
30
2014
|
Net loss and
comprehensive loss
|
(1,190)
|
(79)
|
Amortization of
operating and other assets
|
729
|
-
|
Interest
expense
|
444
|
-
|
EBITDA
|
(17)
|
(79)
|
|
|
|
The following is a reconciliation of Adjusted EBITDA and
Adjusted EBITDA before corporate costs with net loss and
comprehensive loss:
|
|
|
(in thousands of U.S.
Dollars)
|
|
|
|
Three
Months
ended June
30
2015
|
Three
Months
ended June
30
2014
|
Net loss and
comprehensive loss
|
(1,190)
|
(79)
|
Amortization of
operating and other assets
|
729
|
-
|
Interest
expense
|
444
|
-
|
Transaction
costs
|
1,722
|
-
|
Realized gain on
contingent consideration
|
(1,111)
|
-
|
Stock based
compensation
|
29
|
-
|
Adjusted
EBITDA
|
623
|
(79)
|
Corporate costs
(i)
|
641
|
79
|
Adjusted EBITDA
before Corporate costs
|
1,264
|
-
|
Notes:
|
(i)
|
Non-IFRS measure,
Corporate costs excludes stock based compensation,
transaction costs and
amortization.
|
|
|
Syncordia Technologies and Healthcare Solutions,
Corp.
Condensed Interim Consolidated Statement of Financial
Position
As at June 30, 2015
and March 31, 2015
|
|
|
|
|
|
|
|
|
|
(expressed in US
dollars)
|
|
June
30,
2015
$
|
|
March
31,
2015
$
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
Cash and cash
equivalents
|
|
10,286,259
|
|
2,842,413
|
Accounts
receivable
|
|
2,158,778
|
|
1,931,076
|
Other
assets
|
|
277,976
|
|
145,304
|
|
|
|
|
|
|
|
12,723,013
|
|
4,918,793
|
|
|
|
|
|
Property and
equipment
|
|
223,191
|
|
168,418
|
|
|
|
|
|
Intangible
assets (notes 4 and 7)
|
|
18,681,255
|
|
16,134,626
|
|
|
|
|
|
Goodwill
(notes 4 and 7)
|
|
6,559,493
|
|
5,836,719
|
|
|
|
|
|
|
|
38,186,952
|
|
27,058,556
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
Accounts payable and
accrued liabilities
|
|
1,812,369
|
|
1,135,379
|
Holdback payable
(note 4)
|
|
500,000
|
|
-
|
Contingent
consideration payable (note 6)
|
|
-
|
|
2,320,000
|
|
|
|
|
|
|
|
2,312,369
|
|
3,455,379
|
|
|
|
|
|
Notes payable
(note 9)
|
|
11,874,364
|
|
10,483,989
|
|
|
|
|
|
Derivative
financial liability (note 8)
|
|
608,987
|
|
-
|
|
|
|
|
|
Other non-current
liabilities
|
|
40,249
|
|
-
|
|
|
|
|
|
|
|
14,835,969
|
|
13,939,368
|
|
|
|
|
|
Shareholders'
Equity
|
|
|
|
|
|
|
|
|
|
Capital stock
(note 8)
|
|
25,518,248
|
|
14,387,095
|
|
|
|
|
|
Contributed
surplus (notes 8, 9 and 10)
|
|
1,917,320
|
|
1,626,593
|
|
|
|
|
|
Deficit
|
|
(4,084,585)
|
|
(2,894,500)
|
|
|
|
|
|
|
|
23,350,983
|
|
13,119,188
|
|
|
|
|
|
|
|
38,186,952
|
|
27,058,556
|
Commitments
(note 11)
|
|
|
|
|
|
|
|
|
|
Syncordia Technologies and Healthcare Solutions,
Corp.
Condensed Interim Consolidated Statement of Loss and
Comprehensive Loss
For the three-month periods ended June
30, 2015 and 2014
|
|
|
|
|
|
|
|
|
|
(expressed in US
dollars)
|
|
June
30,
2015
$
|
|
June
30,
2014
$
|
|
|
|
|
|
Revenue
|
|
3,392,795
|
|
-
|
|
|
|
|
|
Gain on settlement
of contingent consideration (note 6)
|
|
1,111,342
|
|
-
|
|
|
|
|
|
|
|
4,504,137
|
|
-
|
|
|
|
|
|
Cost of sales
(note 12)
|
|
1,012,732
|
|
-
|
|
|
|
|
|
Amortization of
operating assets (note 7)
|
|
664,331
|
|
-
|
|
|
|
|
|
Gross
profit
|
|
2,827,074
|
|
-
|
|
|
|
|
|
Operating
expenses (notes 10 and 12)
|
|
1,785,923
|
|
78,995
|
|
|
|
|
|
Transaction
costs (note 12)
|
|
1,722,050
|
|
23,000
|
|
|
|
|
|
Other
amortization
|
|
65,300
|
|
-
|
|
|
|
|
|
Loss before
interest expense
|
|
(746,199)
|
|
(101,995)
|
|
|
|
|
|
Interest
expense
|
|
443,886
|
|
-
|
|
|
|
|
|
Net loss and
comprehensive loss for the period
|
|
(1,190,085)
|
|
(101,995)
|
|
|
|
|
|
Net loss per
share
|
|
|
|
|
Basic and diluted
earnings per share
|
|
(0.08)
|
|
(0.03)
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
|
Basic
|
|
15,556,014
|
|
4,063,242
|
Diluted
|
|
18,227,387
|
|
4,063,242
|
|
|
|
|
|
|
|
|
|
|
Syncordia Technologies and Healthcare Solutions,
Corp.
Condensed Interim Consolidated Statement of Cash
Flows
For the three-month periods ended June
30, 2015 and 2014
|
|
|
|
|
|
|
|
|
|
(expressed in US
dollars)
|
|
2015
$
|
|
2014
$
|
|
|
|
|
|
Cash provided by
(used in)
|
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
|
|
|
Net loss for the
period
|
|
(1,190,085)
|
|
(101,995)
|
Items not affecting
cash
|
|
|
|
|
|
Gain on settlement of
contingent consideration (note 6)
|
|
(1,111,342)
|
|
-
|
|
Reverse Takeover
transaction costs (note 5)
|
|
1,068,920
|
|
-
|
|
Amortization
|
|
729,631
|
|
-
|
|
Non-cash interest on
notes payable (note 9)
|
|
157,759
|
|
-
|
|
Share-based
compensation and awards (note 10)
|
|
29,084
|
|
-
|
Changes in non-cash
working capital items
|
|
|
|
|
|
Accounts
receivable
|
|
(141,390)
|
|
(702,617)
|
|
Other
assets
|
|
(84,405)
|
|
-
|
|
Accounts payable and
accrued liabilities
|
|
370,833
|
|
136,527
|
|
Other non-current
liabilities
|
|
40,249
|
|
-
|
|
|
|
|
|
|
|
(130,746)
|
|
(668,085)
|
|
|
|
|
|
Investing
activities
|
|
|
|
|
Purchase of property,
equipment and intangible assets (note 7)
|
|
(68,674)
|
|
-
|
Acquisition of
Paragon (note 4)
|
|
(3,479,929)
|
|
-
|
Settlement of
contingent consideration (note 6)
|
|
(1,208,658)
|
|
-
|
|
|
|
|
|
|
|
(4,757,261)
|
|
-
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
Issuance of Class A
preferred shares
|
|
-
|
|
1,775,000
|
Issuance of Class B
Series 2 preferred shares (note 8)
|
|
3,405,000
|
|
-
|
Issuance of private
placement (note 8)
|
|
8,052,460
|
|
-
|
Cash consideration
from issuance of Reverse Takeover shares (note 5)
|
|
402,605
|
|
-
|
Share issuance costs
(note 8)
|
|
(830,640)
|
|
(37,000)
|
Proceeds from
long-term notes (note 9)
|
|
1,332,388
|
|
-
|
Deferred financing
costs (note 9)
|
|
(29,960)
|
|
-
|
|
|
|
|
|
|
|
12,331,853
|
|
1,738,000
|
|
|
|
|
|
Increase in cash
and cash equivalents during the period
|
|
7,443,846
|
|
1,069,915
|
|
|
|
|
|
Cash and cash
equivalents - Beginning of period
|
|
2,842,413
|
|
3
|
|
|
|
|
|
Cash and cash
equivalents - End of period
|
|
10,286,259
|
|
1,069,918
|
|
|
|
|
|
Cash interest
paid
|
|
286,127
|
|
-
|
|
|
|
|
|
SOURCE Syncordia Technologies and Healthcare Solutions,
Corp.